EP2094293A4 - Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs - Google Patents

Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs

Info

Publication number
EP2094293A4
EP2094293A4 EP07816065A EP07816065A EP2094293A4 EP 2094293 A4 EP2094293 A4 EP 2094293A4 EP 07816065 A EP07816065 A EP 07816065A EP 07816065 A EP07816065 A EP 07816065A EP 2094293 A4 EP2094293 A4 EP 2094293A4
Authority
EP
European Patent Office
Prior art keywords
immune response
treat cancers
tissue targeted
antigenic activation
targeted antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07816065A
Other languages
English (en)
French (fr)
Other versions
EP2094293A1 (de
Inventor
Harold David Gunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qu Biologics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/553,972 external-priority patent/US20070104733A1/en
Application filed by Individual filed Critical Individual
Priority to EP18156810.6A priority Critical patent/EP3338797A1/de
Priority claimed from PCT/CA2007/001915 external-priority patent/WO2008049231A1/en
Publication of EP2094293A1 publication Critical patent/EP2094293A1/de
Publication of EP2094293A4 publication Critical patent/EP2094293A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07816065A 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs Withdrawn EP2094293A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18156810.6A EP3338797A1 (de) 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/553,972 US20070104733A1 (en) 2004-06-07 2006-10-27 Tissue targeted antigenic activation of the immune response to cancers
CA2571805A CA2571805C (en) 2006-10-27 2006-12-20 Tissue targeted antigenic activation of the immune response to cancers
PCT/CA2007/001915 WO2008049231A1 (en) 2006-10-27 2007-10-25 Tissue targeted antigenic activation of the immune response to treat cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP18156810.6A Division EP3338797A1 (de) 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs

Publications (2)

Publication Number Publication Date
EP2094293A1 EP2094293A1 (de) 2009-09-02
EP2094293A4 true EP2094293A4 (de) 2010-09-29

Family

ID=39367058

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07816065A Withdrawn EP2094293A4 (de) 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs
EP18156810.6A Withdrawn EP3338797A1 (de) 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18156810.6A Withdrawn EP3338797A1 (de) 2006-10-27 2007-10-25 Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs

Country Status (4)

Country Link
EP (2) EP2094293A4 (de)
CN (2) CN107412759A (de)
AU (1) AU2007308721B2 (de)
CA (2) CA2997459C (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
EP2242509A1 (de) * 2008-05-29 2010-10-27 Transgene SA Biomarker zur patientenauswahl und entsprechende verfahren
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
CN105816866B (zh) * 2010-07-26 2020-03-06 Qu生物制药公司 免疫原性抗炎组合物
SG187201A1 (en) 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
AU2015252726B2 (en) 2014-05-02 2020-12-24 Qu Biologics Inc. Anti-microbial immunomodulation
CN106011007A (zh) * 2016-06-06 2016-10-12 余国华 多联耐药菌免疫活性蛋白及其制备方法和用途
JP7402805B2 (ja) * 2018-02-06 2023-12-21 エヴェロ バイオサイエンシズ，インコーポレーテッド ベイロネラ（Ｖｅｉｌｌｏｎｅｌｌａ）の細菌を使用して癌及び免疫障害を処置するための組成物及び方法
CN110872632A (zh) * 2018-08-30 2020-03-10 深圳华大生命科学研究院 咽颊炎链球菌的特异基因序列、其检测引物及其应用
CN111560330B (zh) * 2020-05-12 2022-04-26 天津科技大学 一种具有免疫调节、抗炎和抗宫颈癌作用的干酪乳杆菌及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348586B1 (en) * 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
WO2002023994A1 (en) * 2000-09-22 2002-03-28 Mayo Foundation For Medical Education And Research A method for limiting the growth of cancer cells using an attenuated measles virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056387A1 (en) * 2000-02-01 2001-08-09 Donnell Michael A O Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
AU2005251397B2 (en) * 2004-06-07 2010-11-11 Qu Biologics Inc. Bacterial compositions for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348586B1 (en) * 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
WO2002023994A1 (en) * 2000-09-22 2002-03-28 Mayo Foundation For Medical Education And Research A method for limiting the growth of cancer cells using an attenuated measles virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATSUKO FUJIHARA ET AL: "Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 1, 30 June 2007 (2007-06-30), pages 73 - 84, XP019561055, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0351-Y *
BUSSE E ET AL: "INFLUENCE OF CYCLIC AMP LEVEL AND INTERFERON LEVEL IN THE LYMPHOCYTES AND CHANGE IN THE RATE OF TAKING ROOT OF THE TUMOR OF A TRANSPLANTABLE MELANOMA OF THE SYRIAN HAMSTER BY TREATMENT WITH BCG MEASLES VACCINE AS WELL AS L DOPA AND AMANTADINE", RADIOBIOLOGIA RADIOTHERAPIA, vol. 21, no. 3, 1980, pages 292 - 301, XP009137692, ISSN: 0033-8184 *
JAMES MACLEAN ET AL: "Vaccination strategies for the prevention of cervical cancer", EXPERT REVIEW OF ANTICANCER THERAPY, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14737140.5.1.97, vol. 5, no. 1, 1 January 2005 (2005-01-01), pages 97 - 107, XP008110291, ISSN: 1473-7140 *
M. KUROOKA ET AL: "Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells", CANCER RESEARCH, vol. 67, no. 1, 1 January 2007 (2007-01-01), pages 227 - 236, XP055121699, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-1615 *
PFALBERG A ET AL: "Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1046/J.1523-1747.2002.00643.X, vol. 119, no. 3, 1 September 2002 (2002-09-01), pages 570 - 575, XP008109657, ISSN: 0022-202X *
See also references of WO2008049231A1 *

Also Published As

Publication number Publication date
CN107412759A (zh) 2017-12-01
EP3338797A1 (de) 2018-06-27
CA2571805A1 (en) 2008-04-27
CA2997459C (en) 2020-09-22
CA2997459A1 (en) 2008-04-27
CA2571805C (en) 2018-05-01
AU2007308721B2 (en) 2013-06-20
CN101636176A (zh) 2010-01-27
EP2094293A1 (de) 2009-09-02
AU2007308721A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
EP2094293A4 (de) Auf gewebe gezielte antigen-aktivierung der immunantwort zur behandlung von krebs
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
LTC2435432I2 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
EP2341839A4 (de) Auslösung wünschenswerter temperatureffekte auf körpergewebe anhand abwechselnder energiequellen
IL197727A0 (en) Combination treatment of cd38-expressing tumors
EP2041175A4 (de) Gezielte immunkonjugate
EP2076198A4 (de) Herbeiführung gewünschter temperatureffekte auf körpergewebe
PT2642962T (pt) Aparelho de massagem do corpo humano ou animal
ZA200901451B (en) Ultrasonic treatment of glaucoma
ZA200905962B (en) Combination therapy for treatment of immune disorders
EP2125855A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und anderen krankheiten
IL197315A0 (en) Treatment of cancer
EP2049139A4 (de) Behandlung ras-exprimierender tumore
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL200761A0 (en) Body massager
EP2084185A4 (de) Menschliche antikörper zur neutralisierung des menschlichen metapneumovirus
EP2340027A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs
IL214355A0 (en) Antibodies against human tweak and uses thereof
EP2099488A4 (de) Tslp-vakzine zur behandlung von th2-vermittelten entzündlichen erkrankungen
EP2056839A4 (de) Kombinationsverfahren zur krebsbehandlung
ES1070436Y (es) "masajeador corporal"
GB0814043D0 (en) The treatment of skin disorders
GB0602857D0 (en) The treatment of sialorrhoea
GB0600903D0 (en) Treatment of cancer
EP2504347A4 (de) Verstärkung der therapeutischen wirkung einer akupunktur mit adenosin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100827

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20100823BHEP

Ipc: A61P 35/00 20060101ALI20100823BHEP

Ipc: C07K 14/005 20060101ALI20100823BHEP

Ipc: A61K 35/76 20060101ALI20100823BHEP

Ipc: A61P 37/04 20060101ALI20100823BHEP

Ipc: A61P 35/04 20060101ALI20100823BHEP

Ipc: A61K 39/00 20060101AFI20080515BHEP

Ipc: A61K 39/02 20060101ALI20100823BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QU BIOLOGICS INC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUNN, HAROLD D.

17Q First examination report despatched

Effective date: 20120709

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUNN, HAROLD DAVID

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QU BIOLOGICS INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20180215